Corrigendum to: ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress (BioMed Research International (2014) 2014 (807874) DOI: 10.1155/2014/807874);ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Wan, Xiao Shan ^a   Lu, Xiang Hong ^b   Xiao, Ye Cheng ^b   Lin, Yuan ^c   Zhu, Hong ^b   Ding, Ting ^b   Yang, Ying ^b   Huang, Yan ^b   Zhang, Yi ^b   Liu, Yan Long ^b   Xu, Zhu Mei ^b   Xiao, Jian ^b   Li, Xiao Kun ^a,b  

^a JILIN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c Xiamen Hospital of Traditional Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN HOMOLOGOUS PROTEIN; DITHIOTHREITOL; FIBROBLAST GROWTH FACTOR 21; MESSENGER RNA; UNCLASSIFIED DRUG; ATF4 PROTEIN, MOUSE; DDIT3 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PROTEIN BINDING;

ADIPOCYTE; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIVER CELL; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA STABILITY; UPREGULATION; 3T3 CELL LINE; ANIMAL; C57BL MOUSE; CELL LINE; ENDOPLASMIC RETICULUM; GENETIC TRANSCRIPTION; GENETICS; HALF LIFE TIME; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

3T3 CELLS; ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; CELL LINE; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; FIBROBLAST GROWTH FACTORS; HALF-LIFE; MALE; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84901784272     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2018/3218606     Document Type: Erratum

References (49)

1. Beenken A., Mohammadi M., The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery 2009 8 3 235 253 2-s2.0-61649100307 10.1038/nrd2792
2. Olsen S. K., Garbi M., Zampieri N., Eliseenkova A. V., Ornitz D. M., Goldfarb M., Mohammadi M., Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. The Journal of Biological Chemistry 2003 278 36 34226 34236 2-s2.0-0141780824 10.1074/jbc.M303183200 (Pubitemid 37553265)
3. Smallwood P. M., Munoz-Sanjuan I., Tong P., Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proceedings of the National Academy of Sciences of the United States of America 1996 93 18 9850 9857 (Pubitemid 26296698)
4. Kharitonenkov A., Shiyanova T. L., Koester A., Ford A. M., Micanovic R., Galbreath E. J., Sandusky G. E., Hammond L. J., Moyers J. S., Owens R. A., Gromada J., Brozinick J. T., Hawkins E. D., Wroblewski V. J., Li D.-S., Mehrbod F., Jaskunas S. R., Shanafelt A. B., FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005 115 6 1627 1635 2-s2.0-20444435873 10.1172/JCI23606 (Pubitemid 40814671)
5. Kharitonenkov A., Wroblewski V. J., Koester A., Chen Y.-F., Clutinger C. K., Tigno X. T., Hansen B. C., Shanafelt A. B., Etgen G. J., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007 148 2 774 781 2-s2.0-33846418834 10.1210/en.2006-1168 (Pubitemid 46143178)
6. Coskun T., Bina H. A., Schneider M. A., Dunbar J. D., Hu C. C., Chen Y., Moller D. E., Kharitonenkov A., Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008 149 12 6018 6027 2-s2.0-57349098220 10.1210/en.2008-0816
7. Seo J. A., Kim N. H., Fibroblast growth factor 21: a novel metabolic regulator. Diabetes & Metabolism Journal 2012 36 1 26 28
8. Xu J., Lloyd D. J., Hale C., Stanislaus S., Chen M., Sivits G., Vonderfecht S., Hecht R., Li Y.-S., Lindberg R. A., Chen J.-L., Jung D. Y., Zhang Z., Ko H.-J., Kim J. K., Véniant M. M., Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009 58 1 250 259 2-s2.0-61649127208 10.2337/db08-0392
9. Wente W., Efanov A. M., Brenner M., Kharitonenkov A., Köster A., Sandusky G. E., Sewing S., Treinies I., Zitzer H., Gromada J., Fibroblast growth factor-21 improves pancreatic β -cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006 55 9 2470 2478 2-s2.0-33750587755 10.2337/db05-1435 (Pubitemid 44871147)
10. Arner P., Pettersson A., Mitchell P. J., Dunbar J. D., Kharitonenkov A., Rydén M., FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity. FEBS Letters 2008 582 12 1725 1730 2-s2.0-43549110007 10.1016/j.febslet.2008.04.038
11. Mai K., Andres J., Biedasek K., Weicht J., Bobbert T., Sabath M., Meinus S., Reinecke F., Möhlig M., Weickert M. O., Clemenz M., Pfeiffer A. F. H., Kintscher U., Spuler S., Spranger J., Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009 58 7 1532 1538 2-s2.0-67650263853 10.2337/db08-1775
12. Hotta Y., Nakamura H., Konishi M., Murata Y., Takagi H., Matsumura S., Inoue K., Fushiki T., Itoh N., Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009 150 10 4625 4633 2-s2.0-70349324370 10.1210/en.2009-0119
13. Mashili F. L., Austin R. L., Deshmukh A. S., Fritz T., Caidahl K., Bergdahl K., Zierath J. R., Chibalin A. V., Moller D. E., Kharitonenkov A., Krook A., Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes/Metabolism Research and Reviews 2011 27 3 286 297 2-s2.0-79952120254 10.1002/dmrr.1177
14. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., Zhang H., Pan X., Bao Y., Xiang K., Xu A., Jia W., Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology 2010 53 5 934 940 2-s2.0-77957359658 10.1016/j.jhep.2010.05.018
15. Dushay J., Chui P. C., Gopalakrishnan G. S., Varela-Rey M., Crawley M., Fisher F. M., Badman M. K., Martinez-Chantar M. L., Maratos-Flier E., Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010 139 2 456 463 2-s2.0-77955474305 10.1053/j.gastro.2010.04. 054
16. Yilmaz Y., Eren F., Yonal O., Kurt R., Aktas B., Celikel C. A., Ozdogan O., Imeryuz N., Kalayci C., Avsar E., Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. European Journal of Clinical Investigation 2010 40 10 887 892 2-s2.0-77956519052 10.1111/j.1365-2362.2010. 02338.x
17. Chen W.-W., Li L., Yang G.-Y., Li K., Qi X.-Y., Zhu W., Tang Y., Liu H., Boden G., Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes 2008 116 1 65 68 2-s2.0-39449127028 10.1055/s-2007-985148 (Pubitemid 351270911)
18. Li L., Yang G., Ning H., Yang M., Liu H., Chen W., Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Research and Clinical Practice 2008 82 2 209 213 2-s2.0-54549120193 10.1016/j.diabres.2008.07.012
19. Chavez A. O., Molina-Carrion M., Abdul-Ghani M. A., Folli F., DeFronzo R. A., Tripathy D., Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009 32 8 1542 1546 2-s2.0-68149091653 10.2337/dc09-0684
20. Zhang X., Yeung D. C. Y., Karpisek M., Stejskal D., Zhou Z.-G., Liu F., Wong R. L. C., Chow W.-S., Tso A. W. K., Lam K. S. L., Xu A., Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008 57 5 1246 1253 2-s2.0-48349146527 10.2337/db07-1476
21. Mraz M., Bartlova M., Lacinova Z., Michalsky D., Kasalicky M., Haluzikova D., Matoulek M., Dostalova I., Humenanska V., Haluzik M., Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clinical Endocrinology 2009 71 3 369 375 2-s2.0-63849189712 10.1111/j.1365-2265.2008.03502.x
22. Fisher F. M., Estall J. L., Adams A. C., Antonellis P. J., Bina H. A., Flier J. S., Kharitonenkov A., Spiegelman B. M., Maratos-Flier E., Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011 152 8 2996 3004 2-s2.0-79960726293 10.1210/en.2011-0281
23. Badman M. K., Pissios P., Kennedy A. R., Koukos G., Flier J. S., Maratos-Flier E., Hepatic fibroblast growth factor 21 is regulated by PPAR α and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 2007 5 6 426 437 2-s2.0-34249711964 10.1016/j.cmet.2007.05.002 (Pubitemid 46825495)
24. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., Elmquist J. K., Gerard R. D., Burgess S. C., Hammer R. E., Mangelsdorf D. J., Kliewer S. A., Endocrine regulation of the fasting response by PPAR α -mediated induction of fibroblast growth factor 21. Cell Metabolism 2007 5 6 415 425 2-s2.0-34249686631 10.1016/j.cmet.2007.05. 003 (Pubitemid 46825496)
25. Lundåsen T., Hunt M. C., Nilsson L.-M., Sanyal S., Angelin B., Alexson S. E. H., Rudling M., PPAR α is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications 2007 360 2 437 440 2-s2.0-34447265235 10.1016/j.bbrc.2007.06.068 (Pubitemid 47039157)
26. Özcan U., Cao Q., Yilmaz E., Lee A.-H., Iwakoshi N. N., Özdelen E., Tuncman G., Görgün C., Glimcher L. H., Hotamisligil G. S., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004 306 5695 457 461 2-s2.0-5644231992 10.1126/science.1103160 (Pubitemid 39372439)
27. Hotamisligil G. S., Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010 140 6 900 917 2-s2.0-77950343252 10.1016/j.cell.2010.02.034
28. Ozcan L., Tabas I., Role of endoplasmic reticulum stress in metabolic disease and other disorders. Annual Review of Medicine 2012 63 317 328 2-s2.0-84855966721 10.1146/annurev-med-043010-144749
29. Cao S. S., Kaufman R. J., Targeting endoplasmic reticulum stress in metabolic disease. Expert Opinion on Therapeutic Targets 2013 17 4 437 448
30. Kaufman R. J., Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes and Development 1999 13 10 1211 1233 2-s2.0-0033562966 (Pubitemid 29250189)
31. Oyadomari S., Mori M., Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death and Differentiation 2004 11 4 381 389 2-s2.0-1842843855 10.1038/sj.cdd.4401373 (Pubitemid 38489416)
32. Zinszner H., Kuroda M., Wang X., Batchvarova N., Lightfoot R. T., Remotti H., Stevens J. L., Ron D., CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes and Development 1998 12 7 982 995 2-s2.0-0032054744 (Pubitemid 28204605)
33. De Sousa-Coelho A. L., Marrero P. F., Haro D., Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochemical Journal 2012 443 1 165 171 2-s2.0-84858311217 10.1042/BJ20111748
34. Kim K. H., Jeong Y. T., Oh H., Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nature Medicine 2013 19 1 83 92
35. Jiang X., Zhang C., Xin Y., Protective effect of FGF21 on type 1 diabetes-induced testicular apoptotic cell death probably via both mitochondrial- and endoplasmic reticulum stress-dependent pathways in the mouse model. Toxicology Letters 2013 219 1 65 76
36. Luo Y., McKeehan W. L., Stressed liver and muscle call on adipocytes with FGF21. Frontiers in Endocrinology 2013 4 194
37. Schaap F. G., Kremer A. E., Lamers W. H., Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie 2013 95 4 692 699
38. Zhou H., Gurley E. C., Jarujaron S., Ding H., Fang Y., Xu Z., Pandak W. M. Jr., Hylemon P. B., HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. American Journal of Physiology 2006 291 6 G1071 G1080 2-s2.0-33845447823 10.1152/ajpgi.00182.2006 (Pubitemid 44904161)
39. Muise E. S., Azzolina B., Kuo D. W., El-Sherbeini M., Tan Y., Yuan X., Mu J., Thompson J. R., Berger J. P., Wong K. K., Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Molecular Pharmacology 2008 74 2 403 412 2-s2.0-47949111205 10.1124/mol.108.044826
40. Moyers J. S., Shiyanova T. L., Mehrbod F., Dunbar J. D., Noblitt T. W., Otto K. A., Reifel-Miller A., Kharitonenkov A., Molecular determinants of FGF-21 activity-synergy and cross-talk with PPAR γ signaling. Journal of Cellular Physiology 2007 210 1 1 6 2-s2.0-33845407972 10.1002/jcp.20847 (Pubitemid 44904695)
41. Wang H., Qiang L., Farmer S. R., Identification of a domain within peroxisome proliferator-activated receptor γ regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Molecular and Cellular Biology 2008 28 1 188 200 2-s2.0-37549052177 10.1128/MCB.00992-07
42. Cyphert H. A., Ge X., Kohan A. B., Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. The Journal of Biological Chemistry 2012 287 30 25123 25138
43. Iizuka K., Takeda J., Horikawa Y., Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Letters 2009 583 17 2882 2886 2-s2.0-69249238074 10.1016/j.febslet.2009.07.053
44. Wang Y., Solt L. A., Burris T. P., Regulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor α The Journal of Biological Chemistry 2010 285 21 15668 15673 2-s2.0-77952334180 10.1074/jbc.M110.102160
45. Estall J. L., Ruas J. L., Choi C. S., Laznik D., Badman M., Maratos-Flier E., Shulman G. I., Spiegelman B. M., PGC-1 α negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erb α axis. Proceedings of the National Academy of Sciences of the United States of America 2009 106 52 22510 22515 2-s2.0-76049093949 10.1073/pnas.0912533106
46. Schwanhüusser B., Busse D., Li N., Dittmar G., Schuchhardt J., Wolf J., Chen W., Selbach M., Global quantification of mammalian gene expression control. Nature 2011 473 7347 337 342 2-s2.0-79956322553 10.1038/nature10098
47. Brennan C. M., Steitz J. A., HuR and mRNA stability. Cellular and Molecular Life Sciences 2001 58 2 266 277 2-s2.0-0035099573 (Pubitemid 32217358)
48. Raineri I., Wegmueller D., Gross B., Certa U., Moroni C., Roles of AUF1 isoforms, HuR and BRF1 in ARE-dependent mRNA turnover studied by RNA interference. Nucleic Acids Research 2004 32 4 1279 1288 2-s2.0-2542596992 10.1093/nar/gkh282 (Pubitemid 38854729)
49. Lu J.-Y., Schneider R. J., Tissue dstribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay. The Journal of Biological Chemistry 2004 279 13 12974 12979 2-s2.0-1842529308 10.1074/jbc.M310433200 (Pubitemid 38445873)